Review Microbial biotechnology · 2026 Potential Roles of Escherichia coli in IgA Nephropathy: Evidence, Mechanistic Hypotheses and Microbiota-Targeted Strategies. Liu Y, Ning X, Liu Y, et al. Escherichia coli PubMed ↗
Observational Renal failure · 2026 Regulatory effects of leflunomide on gut microecology during IgA nephropathy treatment. Ren P, Wen X, Lin X, et al. Dysosmobacter welbionisIntestinimonas butyriciproducensRuthenibacterium lactatiformans PubMed ↗
Observational Scientific reports · 2025 Reduced butyrate-producing bacteria and altered metabolic pathways in the gut microbiome of immunoglobulin A nephropathy patients. Popova A, Rācenis K, Brīvība M, et al. Agathobacter rectalis PubMed ↗
Review Theranostics · 2025 The evolving understanding of systemic mechanisms in organ-specific IgA nephropathy: a focus on gut-kidney crosstalk. Wang X, Zhou XJ, Qiao X, et al. Akkermansia muciniphila PubMed ↗
Observational Renal failure · 2024 Characteristics and function of the gut microbiota in patients with IgA nephropathy via metagenomic sequencing technology. Deng Y, Nong Z, Wei M, et al. Escherichia coli PubMed ↗
Kidney international · 2026 Therapeutic efficacy and antigenicity of a novel PEGylated IgA protease in preclinical models of IgA nephropathy. Shen X, Shu C, Dong Y, et al. Thomasclavelia ramosa PubMed ↗
Gut microbes · 2025 Targeted modulation of intestinal barrier and mucosal immune-related microbiota attenuates IgA nephropathy progression. Zhang R, Tang Y, Feng X, et al. [Clostridium] leptum PubMed ↗
Science translational medicine · 2024 The gut microbiota posttranslationally modifies IgA1 in autoimmune glomerulonephritis. Gleeson PJ, Benech N, Chemouny J, et al. Akkermansia muciniphila PubMed ↗